On July 15, 2025, Biocon Biologics, a fully integrated global biosimilars company and a subsidiary of Biocon Ltd., announced that the FDA has ...

The US diabetes market presents a substantial opportunity for Biocon Biologics, with 38.4 million people living with diabetes ...

Biocon Biologics expands diabetes portfolio with US FDA approval of Kirsty, an interchangeable rapid-acting insulin aspart in US: Our Bureau, Bengaluru Wednesday, July 16, 2025, 1 ...

“Once-weekly efsitora administered in a fixed-dose regimen was noninferior to once-daily glargine in reducing glycated hemoglobin levels at 52 weeks,” the authors write.

FRIDAY, June 27, 2025 (HealthDay News) -- Once-weekly insulin efsitora alpha (efsitora) is noninferior to once-daily insulin glargine (glargine) for reducing glycated hemoglobin (HbA1c) among ...

If insulin glargine was prescribed, a vial was dispensed regardless of the treatment group because it was not available in a pen device at the start of the study.

Children with diabetes who inhaled their mealtime doses of insulin did just as well as those who injected insulin under the skin, researchers reported at the American Diabetes Association ...

maker Becton, Dickinson and Company Location Currently not on view date made ca 2000 ID Number 2002.0098.10 accession number 2002.0098 catalog number 2002.0098.10 Object Name insulin delivery device ...

Breakthrough studies at the ADA highlight VX-880 stem cell therapy, drastically reducing insulin dependency for type 1 diabetes patients.

Long-lasting insulin takes another step forward with latest clinical trial results Scripps researcher delivers findings for Lilly drug expected to request approval from FDA soon ...

Eli Lilly's orforglipron reduced A1C and weight in type 2 diabetes, while weekly insulin efsitora matched daily insulin with fewer side effects.